Irbesartan + Hidroclorotiazida Fisiofen

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan + Hidroclorotiazida Fisiofen, is an Angiotensin II receptor blocker / Thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Irbesartan + Hidroclorotiazida Fisiofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis.

Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. Essential hypertension: helps achieve target blood pressure when monotherapy is insufficient. Resistant hypertension: provides additional control when other agents have not achieved desired levels.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination or nocturia - Fatigue or weakness - Mild electrolyte disturbances (e.g., low potassium) - Gastrointestinal discomfort such as nausea

Serious or Rare Side Effects: - Angioedema or severe swelling of face, lips, tongue - Significant dehydration or electrolyte imbalance - Hyperkalemia or severe potassium elevation - Acute renal impairment or rise in serum creatinine - Severe hypotension, especially after volume depletion - Allergic reactions including rash or Stevens‑Johnson syndrome

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte balance: watch for hyponatremia, hypokalemia, or hyperkalemia. - Hepatic impairment: use with caution in severe liver disease. - Pregnancy: avoid unless benefits outweigh potential risks. - Concomitant potassium‑sparing agents: increased risk of hyperkalemia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment. - Concurrent ACE inhibitors or other ARBs (risk of renal dysfunction and hyperkalemia). - Potassium supplements or potassium‑sparing diuretics (risk of hyperkalemia).

Moderate Interactions (Monitor Closely): - NSAIDs (may reduce antihypertensive effect and affect renal function). - Lithium (possible increase in lithium levels).